logo-loader

Wall Street shares set to start on front foot, buoyed by Google; European shares also higher

Last updated: 07:12 24 Jul 2018 EDT, First published: 02:12 24 Jul 2018 EDT

1532430832_shutterstock_384985648

US stocks are seen starting on the front foot after a mixed close Monday as quarterly earnings just keep rolling in. European indices are also higher.

The Dow Jones Industrial Average closed down around 13 points at 25,044 but today futures are up 87 points.

The broader based S&P 500  closed up around five points at 2,806 and futures are today ahead by 5.25 points.

The tech heavy Nasdaq was a stronger gainer on Monday after earnings with the benchmark closing around 21 points higher at 7,841.

Nasdaq futures are today up eight points.

There are a myriad of US firms posting results today ahead of the New York bell, including Harley Davidson (NYSE:HOG), Eli Lilly And Co (NYSE:LLY)  and Verizon Communications Inc (NYSE:VZ)

In Europe shares were upbeat this morning following the positive reception to Google parent Alphabet’s (NASDAQ:GOOGL) earnings last night.

But a fall in the Eurozone-wide manufacturing and services PMIs prevented the euro currency from taking off,  noted Connor Campbell, financial analyst at Spreadex.

In London, at the time of writing, the FTSE 100 is  up around 65 points at 7,721, while the German DAX is surging over 168 points and the  CAC 40 is up 45 at 5,423.

Campbell, looking towards US trade later, said the Dow Jones looked "set to benefit from Google’s driver high..".

"In terms of data, the month’s flash manufacturing and services PMIs are set to slip to 55.1 and remain unchanged at 56.5 respectively," he added.

In Asia, the Nikkei 225 added over 113 points at 22,510, while the Shanghai Composite Index added around 46 at 2,905.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 28 minutes ago